10-Q 1 tm2014573d1_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2020

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File No. 000-53501

RESEARCH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	11-3797644
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

16350 Ventura Blvd., Suite D #811, Encino, California	91436
(Address of principal executive offices)	(Zip Code)

(310) 477-0354

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each Exchange on which registered
Common stock, $0.001 par value	RSSS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer þ	Smaller reporting company þ
	Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Title of Class		Number of Shares Outstanding on May 7, 2020
Common Stock, $0.001 par value		26,034,572

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION		3
Item 1. Condensed Consolidated Financial Statements (unaudited)		3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 3. Quantitative and Qualitative Disclosures About Market Risk		29
Item 4. Controls and Procedures		29

PART II — OTHER INFORMATION		30
Item 1A. Risk Factors		30
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		30
Item 6. Exhibits		30

SIGNATURES		31

PART 1 — FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	March 31,			June 30,
	2020			2019
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	8,249,260		$	5,353,090
Accounts receivable, net of allowance of $88,698 and $100,175, respectively		5,111,493			4,493,169
Prepaid expenses and other current assets		307,165			323,591
Prepaid royalties		566,379			-
Total current assets		14,234,297			10,169,850

Other assets:
Property and equipment, net of accumulated depreciation of $799,935 and $789,788, respectively		14,822			36,828
Deposits and other assets		6,132			14,406
Right of use asset, net of accumulated amortization of $360,239 and $270,777, respectively		102,783			192,245
Total assets	$	14,358,034		$	10,413,329

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	6,174,737		$	4,862,895
Deferred revenue		3,302,187			2,310,206
Lease liability, current portion		112,775			129,187
Total current liabilities		9,589,699			7,302,288

Long-term liabilities:
Lease liability, long-term portion		-			79,326
Total liabilities		9,589,699			7,381,614

Commitments and contingencies

Stockholders’ equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock; $0.001 par value; 100,000,000 shares authorized; 26,034,572 and 24,375,948 shares issued and outstanding, respectively		26,035			24,376
Additional paid-in capital		26,044,827			23,631,481
Accumulated deficit		(21,176,240	)		(20,514,557	)
Accumulated other comprehensive loss		(126,287	)		(109,585	)
Total stockholders’ equity		4,768,335			3,031,715
Total liabilities and stockholders’ equity	$	14,358,034		$	10,413,329

See notes to condensed consolidated financial statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2020			2019			2020			2019

Revenue:
Platforms	$	1,017,789		$	748,726		$	2,824,059		$	2,005,284
Transactions		7,029,617			6,629,231			20,348,898			19,314,036
Total revenue		8,047,406			7,377,957			23,172,957			21,319,320

Cost of revenue:
Platforms		177,919			134,672			490,897			365,007
Transactions		5,330,473			5,063,624			15,552,711			14,838,457
Total cost of revenue		5,508,392			5,198,296			16,043,608			15,203,464
Gross profit		2,539,014			2,179,661			7,129,349			6,115,856

Operating expenses:
Selling, general and administrative		2,544,659			2,343,161			7,956,446			7,156,937
Depreciation and amortization		5,510			9,617			19,908			30,465
Total operating expenses		2,550,169			2,352,778			7,976,354			7,187,402
Loss from operations		(11,155	)		(173,117	)		(847,005	)		(1,071,546	)

Other income		23,662			27,875			75,738			75,124

Income (loss) from operations before provision for income taxes		12,507			(145,242	)		(771,267	)		(996,422	)
Provision for income taxes		(561	)		(5,482	)		(7,861	)		(22,145	)

Income (loss) from continuing operations		11,946			(150,724	)		(779,128	)		(1,018,567	)

Gain from sale of discontinued operations		-			33,044			117,445			130,462

Net income (loss)		11,946			(117,680	)		(661,683	)		(888,105	)

Other comprehensive income (loss):
Foreign currency translation		(14,677	)		(5,216	)		(16,702	)		(11,254	)
Comprehensive loss	$	(2,731	)	$	(122,896	)	$	(678,385	)	$	(899,359	)

Basic income (loss) per common share:
Income (loss) per share from continuing operations	$	-		$	-		$	(0.03	)	$	(0.04	)
Income per share from discontinued operations	$	-		$	-		$	-		$	-
Net income (loss) per share	$	-		$	-		$	(0.03	)	$	(0.04	)
Basic weighted average common shares outstanding		24,960,394			23,845,798			24,411,888			23,758,844

Diluted income (loss) per common share:
Income (loss) per share from continuing operations	$	-		$	-		$	(0.03	)	$	(0.04	)
Income per share from discontinued operations	$	-		$	-		$	-		$	-
Net income (loss) per share	$	-		$	-		$	(0.03	)	$	(0.04	)
Diluted weighted average common shares outstanding		25,717,403			23,845,798			24,411,888			23,758,844

See notes to condensed consolidated financial statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders' Equity

For the Nine Months Ended March 31, 2020

(Unaudited)

	Common Stock						Additional Paid-in			Accumulated			Other Comprehensive			Total Stockholders'
	Shares			Amount			Capital			Deficit			Loss			Equity

Balance, July 1, 2019		24,375,948		$	24,376		$	23,631,481		$	(20,514,557	)	$	(109,585	)	$	3,031,715

Fair value of vested stock options		-			-			58,198			-			-			58,198

Fair value of vested restricted common stock		70,000			70			84,404			-			-			84,474

Repurchase of common stock		(28,750	)		(28	)		(71,847	)		-			-			(71,875	)

Common stock issued upon exercise of stock options		24,307			24			(24	)		-			-			-

Net loss for the period		-			-			-			(81,457	)		-			(81,457	)

Foreign currency translation		-			-			-			-			(3,568	)		(3,568	)

Balance, September 30, 2019		24,441,505			24,442			23,702,212			(20,596,014	)		(113,153	)		3,017,487

Fair value of vested stock options		-			-			437,992			-			-			437,992

Fair value of vested restricted common stock		13,978			14			85,626			-			-			85,640

Repurchase of common stock		(42,500	)		(42	)		(127,457	)		-			-			(127,499	)

Common stock issued upon exercise of stock options		62,573			62			(62	)		-			-			-

Net loss for the period		-			-			-			(592,172	)		-			(592,172	)

Foreign currency translation		-			-			-			-			1,543			1,543

Balance, December 31, 2019		24,475,556			24,476			24,098,311			(21,188,186	)		(111,610	)		2,822,991

Fair value of vested stock options		-			-			56,712			-			-			56,712

Fair value of vested restricted common stock		12,500			13			85,513			-			-			85,526

Repurchase of common stock		(25,150	)		(25	)		(69,138	)		-			-			(69,163	)

Common stock issued upon exercise of stock options		71,666			71			(71	)		-			-			-

Common stock issued upon exercise of warrants		1,500,000			1,500			1,873,500			-			-			1,875,000

Net income for the period		-			-			-			11,946			-			11,946

Foreign currency translation		-			-			-			-			(14,677	)		(14,677	)

Balance, March 31, 2020		26,034,572		$	26,035		$	26,044,827		$	(21,176,240	)	$	(126,287	)	$	4,768,335

See notes to condensed consolidated financial statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders' Equity

For the Nine Months Ended March 31, 2019

(Unaudited)

	Common Stock						Additional Paid-in			Accumulated			Other Comprehensive			Total Stockholders'
	Shares			Amount			Capital			Deficit			Loss			Equity

Balance, July 1, 2018		24,016,999		$	24,017		$	22,904,691		$	(19,554,599	)	$	(94,707	)	$	3,279,402

Fair value of vested stock options		-			-			39,648			-			-			39,648

Fair value of vested restricted common stock		130,127			130			76,131			-			-			76,261

Repurchase of common stock		(34,200	)		(34	)		(75,166	)		-			-			(75,200	)

Common stock issued upon exercise of stock options		3,750			4			(4	)		-			-			-

Common stock issued upon exercise of warrants		39,000			39			(39	)		-			-			-

Net loss for the period		-			-			-			(177,888	)		-			(177,888	)
		-
Foreign currency translation					-			-			-			(4,370	)		(4,370	)

Balance, September 30, 2018		24,155,676			24,156			22,945,261			(19,732,487	)		(99,077	)		3,137,853

Fair value of vested stock options		-			-			375,795			-			-			375,795

Fair value of vested restricted common stock		20,087			20			77,473			-			-			77,493

Repurchase of common stock		(15,800	)		(16	)		(38,062	)		-			-			(38,078	)

Common stock issued upon exercise of stock options		79,050			79			(79	)		-			-			-

Net loss for the period		-			-			-			(592,537	)		-			(592,537	)

Foreign currency translation		-			-			-			-			(1,668	)		(1,668	)

Balance, December 31, 2018		24,239,013			24,239			23,360,388			(20,325,024	)		(100,745	)		2,958,858

Fair value of vested stock options		-			-			55,795			-			-			55,795

Fair value of vested restricted common stock		12,148			12			75,265			-			-			75,277

Repurchase of common stock		(20,500	)		(20	)		(45,900	)		-			-			(45,920	)

Net loss for the period		-			-			-			(117,680	)		-			(117,680	)

Foreign currency translation		-			-			-			-			(5,216	)		(5,216	)

Balance, March 31, 2019		24,230,661		$	24,231		$	23,445,548		$	(20,442,704	)	$	(105,961	)	$	2,921,114

See notes to condensed consolidated financial statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	March 31,
	2020			2019

Cash flow from operating activities:
Net loss	$	(661,683	)	$	(888,105	)
Adjustment to reconcile net loss to net cash provided by operating activities:
Gain from sale of discontinued operations		(117,445	)		(130,462	)
Depreciation and amortization		19,908			30,465
Amortization of lease right		89,462			85,870
Fair value of vested stock options		552,902			471,238
Fair value of vested restricted common stock		255,640			229,031
Changes in operating assets and liabilities:
Accounts receivable		(618,324	)		(115,724	)
Prepaid expenses and other current assets		133,871			177,973
Prepaid royalties		(566,379	)		(647,387	)
Deposits and other assets		8,094			-
Accounts payable and accrued expenses		1,311,842			1,047,266
Deferred revenue		991,981			403,709
Lease liability		(95,738	)		(88,744	)
Net cash provided by operating activities		1,304,131			575,130

Cash flow from investing activities:
Purchase of property and equipment		-			(9,107	)
Net cash used in investing activities		-			(9,107	)

Cash flow from financing activities:
Proceeds from the exercise of warrants		1,875,000			-
Common stock repurchase and retirement		(268,537	)		(159,198	)
Net cash provided by (used in) financing activities		1,606,463			(159,198	)

Effect of exchange rate changes		(14,424	)		(11,921	)
Net increase in cash and cash equivalents		2,896,170			394,904
Cash and cash equivalents, beginning of period		5,353,090			4,908,180
Cash and cash equivalents, end of period	$	8,249,260		$	5,303,084

Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	7,861		$	22,145

See notes to condensed consolidated financial statements

RESEARCH SOLUTIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Nine Months Ended March 31, 2020 and 2019 (Unaudited)

Note 1. Organization, Nature of Business and Basis of Presentation

Organization

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico.

Nature of Business

We provide two service offerings to our customers: annual licenses that allow customers to access and utilize certain premium features of our cloud based software-as-a-service (“SaaS”) research intelligence platform (“Platforms”) and the transactional sale of published scientific, technical, and medical (“STM”) content managed, sourced and delivered through the Platform (“Transactions”). Platforms and Transactions are packaged as a single solution that enable life science and other research intensive organizations to speed up research and development activities with faster, single sourced access and management of content and data used throughout the intellectual property development lifecycle.

Platforms

Our cloud-based SaaS research intelligence platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

Additional functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering, identification and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

Transactions

Our Platform provides our customers with a single source to the universe of published STM content that includes over 70 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

Principles of Consolidation

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2019 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer's financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer's financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros with a US Dollar equivalent of $136,896 and $63,933 at March 31, 2020 and June 30, 2019, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2020 and 2019.

The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2020 and June 30, 2019.

The following table summarizes vendor concentrations:

	Three Months Ended March 31,						Nine Months Ended March 31,
	2020			2019			2020			2019
Vendor A		19	%		16	%		21	%		18	%
Vendor B		13	%		12	%		13	%		12	%
Vendor C		*			*			*			11	%

* Less than 10%

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

•

identify the contract with a customer;

•

identify the performance obligations in the contract;

•

determine the transaction price;

•

allocate the transaction price to performance obligations in the contract; and

•

recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Deferred Revenue

Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations.

In prior periods through June 30, 2019, the Company accounted for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

On July 1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions will be measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions. The adoption of the standard did not have a material impact on our financial statements.

Foreign Currency

The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to loss of $8,648 and $2,302 for the three months ended March 31, 2020 and 2019, respectively and loss of $15,315 and $17,307 for the nine months ended March 31, 2020 and 2019, respectively. Cash denominated in Euros with a US Dollar equivalent of $136,896 and $63,933 at March 31, 2020 and June 30, 2019, respectively, was held in accounts at financial institutions located in Europe.

The following table summarizes the exchange rates used:

	Nine Months Ended March 31,				Year Ended June 30,
	2020		2019		2019		2018
Period end Euro : US Dollar exchange rate		1.10		1.12		1.14		1.17
Average period Euro : US Dollar exchange rate		1.11		1.15		1.14		1.19

Period end Mexican Peso : US Dollar exchange rate		0.04		0.05		0.05		0.05
Average period Mexican Peso : US Dollar exchange rate		0.05		0.05		0.05		0.05

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2020 potentially dilutive securities include options to acquire 3,324,580 shares of common stock, warrants to acquire 385,000 shares of common stock and unvested restricted common stock of 219,926. At March 31, 2019 potentially dilutive securities include options to acquire 3,465,335 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 356,759. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

Basic and diluted net loss per common share is the same for the nine months ended March 31, 2020 and the three and nine months ended March 31, 2019 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three months ended March 31, 2020, the calculation of diluted earnings per share includes unvested restricted common stock, stock options and warrants, calculated under the treasury stock method.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments ("ASC 326"). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today's "incurred loss" approach with an "expected loss" model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard's provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company's financial position, results of operations, and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Note 3. Line of Credit

The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 14, 2022, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2020. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest equal to the greater of 1% above the prime rate and 5.5%. The interest rate on the line of credit was 5.5% as of March 31, 2020. The line of credit is secured by the Company’s consolidated assets.

There were no outstanding borrowings under the line as of March 31, 2020 and June 30, 2019, respectively. As of March 31, 2020, there was approximately $2,458,000 of available credit.

Note 4. Lease Obligations

On December 30, 2016, the Company entered into a 48 month non-cancellable lease for its office facilities that will require monthly payments ranging from $10,350 to $11,475 through January 2021. In accounting for the lease, the Company adopted ASU 2016-02, Leases which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease assets and liability at the inception of the lease was $463,000 using a discount rate of 3.75%. During the nine months ended March 31, 2020, the Company made payments of $95,738 towards the lease liability. As of March 20, 2020 and June 30, 2019, lease liability amounted to $112,775 and $208,513, respectively. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense, including real estate taxes, for the nine months ended March 31, 2020 and 2019 was $97,275 and $108,912, respectively. The right of use asset at June 30, 2019 was $192,245. During the nine months ended March 31, 2020, the Company reflected amortization of right of use asset of $89,462 related to this lease, resulting in a net asset balance of $102,783 as of March 31, 2020.

On October 8, 2019, the Company entered into an agreement to sublease its office facilities from November 1, 2019 through January 31, 2021, the end of the lease term, for $8,094 per month with one month of abated rent. The Company recorded rent income of $27,789 during the nine months ended March 31, 2020, included in general and administrative expenses in the accompanying statements of operations.

Note 5. Stockholders’ Equity

Stock Options

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 12, 2019, the Company’s stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 1,874,513 to 2,374,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of March 31, 2020, there were 644,768 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

The following table summarizes vested and unvested stock option activity:

	All Options					Vested Options					Unvested Options
	Shares			Weighted Average Exercise Price		Shares			Weighted Average Exercise Price		Shares			Weighted Average Exercise Price
Outstanding at June 30, 2019		3,287,335		$	1.38		2,827,251		$	1.27		460,084		$	2.09
Granted		316,000			3.04		250,000			3.13		66,000			2.69
Options vesting		-			-		229,582			2.03		(229,582	)		2.03
Exercised		(258,755	)		1.17		(258,755	)		1.17		-			-
Forfeited/Cancelled		(20,000	)		1.95		(10,000	)		1.95		(10,000	)		1.95
Outstanding at March 31, 2020		3,324,580		$	1.56		3,038,078		$	1.49		286,502		$	2.28

The weighted average remaining contractual life of all options outstanding as of March 31, 2020 was 5.99 years. The remaining contractual life for options vested and exercisable at March 31, 2020 was 5.73 years. Furthermore, the aggregate intrinsic value of options outstanding as of March 31, 2020 was $4,810,855, and the aggregate intrinsic value of options vested and exercisable at March 31, 2020 was $4,595,160, in each case based on the fair value of the Company’s common stock on March 31, 2020.

During the nine months ended March 31, 2020, the Company granted 316,000 options to employees with a fair value of $475,840. The total fair value of options that vested during the nine months ended March 31, 2020 was $552,902 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of March 31, 2020, the amount of unvested compensation related to stock options was $336,006 which will be recorded as an expense in future periods as the options vest. During the nine months ended March 31, 2020, the Company issued 158,546 net shares of common stock upon the exercise of 258,755 options on a cashless basis.

The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2020 and 2019.

	Nine Months Ended March 31,
	2020	2019
Expected dividend yield	0%	0%
Risk-free interest rate	1.37% - 1.69%	2.82% – 3.00%
Expected life (in years)	5 - 6	5 - 6
Expected volatility	62 - 64%	68 - 69%

Additional information regarding stock options outstanding and exercisable as of March 31, 2020 is as follows:

Option Exercise Price		Options Outstanding		Remaining Contractual Life (in years)		Options Exercisable
	$0.59		8,150		2.25		8,150
	0.60		5,000		2.25		5,000
	0.65		6,150		2.25		6,150
	0.70		225,000		5.68		225,000
	0.77		49,500		3.33		49,500
	0.80		16,000		5.39		16,000
	0.90		25,667		4.06		25,667
	0.97		6,000		2.25		6,000
	1.00		28,249		3.68		28,249
	1.02		87,000		0.37		87,000
	1.05		400,529		6.34		400,529
	1.07		33,898		2.54		33,898
	1.09		129,165		5.61		129,165
	1.10		105,000		5.25		105,000
	1.14		3,674		2.25		3,674
	1.15		209,400		4.36		209,400
	1.20		352,414		7.33		348,746
	1.25		32,000		2.87		32,000
	1.30		243,000		1.93		243,000
	1.50		195,000		2.63		195,000
	1.59		35,000		8.12		23,333
	1.75		1,067		2.25		1,067
	1.80		94,050		3.38		94,050
	1.85		24,000		2.84		24,000
	1.95		275,000		8.26		166,667
	2.40		398,667		8.63		321,833
	2.49		50,000		9.50		-
	2.50		20,000		9.13		-
	3.13		258,000		9.62		250,000
	3.50		8,000		9.87		-
	Total		3,324,580				3,038,078

Warrants

The following table summarizes warrant activity:

	Number of Warrants			Weighted Average Exercise Price
Outstanding, June 30, 2019		1,885,000		$	1.25
Granted		-			-
Exercised		(1,500,000	)		1.25
Expired/Cancelled		-			-
Outstanding, March 31, 2020		385,000		$	1.24
Exercisable, June 30, 2019		1,885,000		$	1.25
Exercisable, March 31, 2020		385,000		$	1.24

The intrinsic value for all warrants outstanding as of March 31, 2020 was $1,061,750, based on the fair value of the Company’s common stock on March 31, 2020.

On February 19 and 20, 2020, certain holders of warrants to purchase shares of the Company’s common stock at a per share exercise price of $1.25 exercised those warrants to purchase 1,500,000 shares, generating gross proceeds to the Company of $1,875,000.

Additional information regarding warrants outstanding and exercisable as of March 31, 2020 is as follows:

Warrant Exercise Price		Warrants Outstanding		Remaining Contractual Life (in years)		Warrants Exercisable
$	1.19		50,000		1.73		50,000
	1.25		335,000		1.14		335,000
	Total		385,000				385,000

Restricted Common Stock

Prior to July 1, 2019, the Company issued 2,166,549 shares of restricted common stock to employees valued at $2,386,443, of which 1,640,690 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $1,785,857 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 311,535 at June 30, 2019.

During the nine months ended March 31, 2020, the Company issued an additional 96,478 shares of restricted stock to employees. These shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was $280,001 based on the market price of our common stock price of $2.90 per share on the date of grant, which will be amortized over the three-year vesting period.

The total fair value of restricted common stock vesting during the nine months ended March 31, 2020 was $255,640 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of March 31, 2020, the amount of unvested compensation related to issuances of restricted common stock was $436,744, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income (loss) per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date.

The following table summarizes restricted common stock activity:

	Number of Shares			Fair Value			Weighted Average Grant Date Fair Value
Non-vested, June 30, 2019		311,535		$	412,383		$	1.66
Granted		96,478			280,001			2.90
Vested		(188,087	)		(255,640	)		1.57
Forfeited		-			-			-
Non-vested, March 31, 2020		219,926		$	436,744		$	2.29

Common Stock Repurchase and Retirement

Effective as of February 11, 2020, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2020 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors.

During the nine months ended March 31, 2020, the Company repurchased 96,400 shares of our common stock from employees at an average market price of approximately $2.80 per share for an aggregate amount of $268,537.

As of March 31, 2020, $330,838 remains available under the 2020 plan to repurchase common stock from its employees. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

Note 6. Gain from Sale of Discontinued Operations (Reprints and ePrints business line)

On June 30, 2017, we sold the intangible assets of our Reprints and ePrints business pursuant to an Asset Purchase Agreement dated June 20, 2017. The aggregate net consideration for the sale included earn-out payments of 45% of gross margin over the 30-month period subsequent to the closing date. We have made a policy election to record the contingent consideration when the consideration is determined to be realizable (each 6-month period ending subsequent to the closing date). Realizable contingent consideration amounted to $117,445 for the nine months ended March 31, 2020 and is recorded as a gain from the sale of discontinued operations.

Note 7. Contingencies

COVID-19

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows.

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations for the three and nine months ended March 31, 2020 and 2019 should be read in conjunction with our consolidated financial statements and related notes to those financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019.

We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements.

Overview

Research Solutions was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries at June 30, 2019: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico.

Platforms

Transactions

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions.

The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to an understanding of our financial statements because they inherently involve significant judgments and uncertainties.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. We adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We derive our revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

•

identify the contract with a customer;

•

identify the performance obligations in the contract;

•

determine the transaction price;

•

allocate the transaction price to performance obligations in the contract; and

•

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Stock-Based Compensation

We periodically issue stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. We account for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations.

In prior periods through June 30, 2019, we accounted for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

On July 1, 2019, we adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions will be measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions. The adoption of the standard did not have a material impact on our financial statements.

Recent Accounting Pronouncements

Please refer to footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q for a discussion of Recent Accounting Pronouncements.

Quarterly Information (Unaudited)

The following table sets forth unaudited and quarterly financial data for the most recent eight quarters:

	Mar. 31,		Dec. 31,			Sept. 30,			June 30,			Mar. 31,			Dec. 31,			Sept. 30,			June 30,
	2020		2019			2019			2019			2019			2018			2018			2018
Revenue:
Platforms	$	1,017,789	$	949,825		$	856,445		$	803,917		$	748,726		$	667,545		$	589,013		$	528,581
Transactions		7,029,617		6,580,613			6,738,668			6,670,685			6,629,231			6,321,297			6,363,508			6,637,292
Total revenue		8,047,406		7,530,438			7,595,113			7,474,602			7,377,957			6,988,842			6,952,521			7,165,873

Cost of revenue:
Platforms		177,919		162,508			150,470			142,368			134,672			122,077			108,259			101,370
Transactions		5,330,473		5,094,130			5,128,108			5,104,629			5,063,624			4,878,526			4,896,307			5,118,851
Total cost of revenue		5,508,392		5,256,638			5,278,578			5,246,997			5,198,296			5,000,603			5,004,566			5,220,221

Gross profit:
Platforms		839,870		787,317			705,975			661,549			614,054			545,468			480,754			427,211
Transactions		1,699,144		1,486,483			1,610,560			1,566,056			1,565,607			1,442,771			1,467,201			1,518,441
Total gross profit		2,539,014		2,273,800			2,316,535			2,227,605			2,179,661			1,988,239			1,947,955			1,945,652

Operating expenses:
Sales and marketing		626,956		638,837			550,349			659,108			542,641			445,879			431,417			455,250
Technology and product dev.		536,238		548,719			499,191			549,198			537,685			553,272			499,795			454,053
General and administrative		1,230,580		1,270,375			1,231,345			1,060,269			1,129,461			1,180,599			1,118,611			1,062,981
Depreciation and amortization		5,510		6,840			7,558			8,351			9,617			9,733			11,115			32,731
Stock-based comp. expense		142,237		523,632			142,672			126,903			131,072			453,288			115,909			75,089
Foreign currency transaction loss (gain)		8,648		(5,456	)		12,123			7,193			2,302			10,025			4,980			14,589
Total operating expenses		2,550,169		2,982,947			2,443,238			2,411,022			2,352,778			2,652,796			2,181,827			2,094,693
Other income (expenses and income taxes)		23,101		25,721			19,055			27,289			22,393			16,322			14,264			12,615
Income (loss) from continuing operations		11,946		(683,426	)		(107,648	)		(156,128	)		(150,724	)		(648,235	)		(219,608	)		(136,426	)
Gain on sale of discontinued operations		-		91,254			26,191			84,275			33,044			55,698			41,720			51,216
Net income (loss)		11,946		(592,172	)		(81,457	)		(71,853	)		(117,680	)		(592,537	)		(177,888	)		(85,210	)

Basic income (loss) per common share:
Income (loss) per share from continuing operations	$	-	$	(0.03	)	$	-		$	-		$	-		$	(0.03	)	$	(0.01	)	$	(0.01	)
Income per share from discontinued operations	$	-	$	-		$	-		$	-		$	-		$	-		$	-		$	-
Net income (loss) per share	$	-	$	(0.03	)	$	-		$	-		$	-		$	(0.03	)	$	(0.01	)	$	(0.01	)
Basic weighted average common shares outstanding		24,960,394		24,185,966			24,095,266			23,987,137			23,845,798			23,787,836			23,644,787			23,560,781

Diluted income (loss) per common share:
Income (loss) per share from continuing operations	$	-	$	(0.03	)	$	-		$	-		$	-		$	(0.03	)	$	(0.01	)	$	(0.01	)
Income per share from discontinued operations	$	-	$	-		$	-		$	-		$	-		$	-		$	-		$	-
Net income (loss) per share	$	-	$	(0.03	)	$	-		$	-		$	-		$	(0.03	)	$	(0.01	)	$	(0.01	)
Diluted weighted average common shares outstanding		25,717,403		24,185,966			24,095,266			23,987,137			23,845,798			23,787,836			23,644,787			23,560,781

Comparison of the Three and Nine Months Ended March 31, 2020 and 2019

Results of Operations

	Three Months Ended March 31,
	2020			2019			$ Change			% Change

Revenue:
Platforms	$	1,017,789		$	748,726		$	269,063			35.9	%
Transactions		7,029,617			6,629,231			400,386			6.0	%
Total revenue		8,047,406			7,377,957			669,449			9.1	%

Cost of revenue:
Platforms		177,919			134,672			43,247			32.1	%
Transactions		5,330,473			5,063,624			266,849			5.3	%
Total cost of revenue		5,508,392			5,198,296			310,096			6.0	%

Gross profit:
Platforms		839,870			614,054			225,816			36.8	%
Transactions		1,699,144			1,565,607			133,537			8.5	%
Total gross profit		2,539,014			2,179,661			359,353			16.5	%

Operating expenses:
Sales and marketing		626,956			542,641			84,315			15.5	%
Technology and product development		536,238			537,685			(1,447	)		(0.3	)%
General and administrative		1,230,580			1,129,461			101,119			9.0	%
Depreciation and amortization		5,510			9,617			(4,107	)		(42.7	)%
Stock-based compensation expense		142,237			131,072			11,165			8.5	%
Foreign currency transaction loss (gain)		8,648			2,302			6,346			275.7	%
Total operating expenses		2,550,169			2,352,778			197,391			8.4	%
Loss from operations		(11,155	)		(173,117	)		161,962			93.6	%

Other income		23,662			27,875			(4,213	)		(15.1	)%

Income (loss) from operations before provision for income taxes		12,507			(145,242	)		157,749			108.6	%
Provision for income taxes		(561	)		(5,482	)		4,921			89.8	%

Income (loss) from continuing operations		11,946			(150,724	)		162,670			107.9	%

Gain from sale of discontinued operations		-			33,044			(33,044	)		(100.0	)%

Net income (loss)	$	11,946		$	(117,680	)	$	129,626			110.2	%

	Nine Months Ended March 31,
	2020			2019			$ Change			% Change

Revenue:
Platforms	$	2,824,059		$	2,005,284		$	818,775			40.8	%
Transactions		20,348,898			19,314,036			1,034,862			5.4	%
Total revenue		23,172,957			21,319,320			1,853,637			8.7	%

Cost of revenue:
Platforms		490,897			365,007			125,890			34.5	%
Transactions		15,552,711			14,838,457			714,254			4.8	%
Total cost of revenue		16,043,608			15,203,464			840,144			5.5	%

Gross profit:
Platforms		2,333,162			1,640,277			692,885			42.2	%
Transactions		4,796,187			4,475,579			320,608			7.2	%
Total gross profit		7,129,349			6,115,856			1,013,493			16.6	%

Operating expenses:
Sales and marketing		1,816,142			1,419,937			396,205			27.9	%
Technology and product development		1,584,148			1,590,752			(6,604	)		(0.4	)%
General and administrative		3,732,300			3,428,672			303,628			8.9	%
Depreciation and amortization		19,908			30,465			(10,557	)		(34.7	)%
Stock-based compensation expense		808,541			700,269			108,272			15.5	%
Foreign currency transaction loss (gain)		15,315			17,307			(1,992	)		(11.5	)%
Total operating expenses		7,976,354			7,187,402			788,952			11.0	%
Loss from operations		(847,005	)		(1,071,546	)		224,541			21.0	%

Other income		75,738			75,124			614			0.8	%

Loss from operations before provision for income taxes		(771,267	)		(996,422	)		225,155			22.6	%
Provision for income taxes		(7,861	)		(22,145	)		14,284			64.5	%

Loss from continuing operations		(779,128	)		(1,018,567	)		239,439			23.5	%

Gain from sale of discontinued operations		117,445			130,462			(13,017	)		(10.0	)%

Net loss	$	(661,683	)	$	(888,105	)	$	226,422			25.5	%

Revenue

	Three Months Ended March 31,
	2020		2019		$ Change		% Change
Revenue:
Platforms	$	1,017,789	$	748,726	$	269,063		35.9	%
Transactions		7,029,617		6,629,231		400,386		6.0	%
Total revenue	$	8,047,406	$	7,377,957	$	669,449		9.1	%

Total revenue increased $669,449, or 9.1%, for the three months ended March 31, 2020 compared to the prior year, due to the following:

Category	Impact			Key Drivers
Platforms	↑	$	269,063	Increased due to additional deployments to new and existing customers, and expansion from existing customers. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	400,386	Increased primarily due to orders from new customers.

	Nine Months Ended March 31,
	2020		2019		$ Change		% Change
Revenue:
Platforms	$	2,824,059	$	2,005,284	$	818,775		40.8	%
Transactions		20,348,898		19,314,036		1,034,862		5.4	%
Total revenue	$	23,172,957	$	21,319,320	$	1,853,637		8.7	%

Total revenue increased $1,853,637, or 8.7%, for the nine months ended March 31, 2020 compared to the prior year, due to the following:

Category	Impact			Key Drivers
Platforms	↑	$	818,775	Increased due to additional deployments to new and existing customers, and expansion from existing customers. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	1,034,862	Increased primarily due to orders from new customers.

Cost of Revenue

	Three Months Ended March 31,
	2020		2019		$ Change		% Change
Cost of Revenue:
Platforms	$	177,919	$	134,672	$	43,247		32.1	%
Transactions		5,330,473		5,063,624		266,849		5.3	%
Total cost of revenue	$	5,508,392	$	5,198,296	$	310,096		6.0	%

	Three Months Ended March 31,
	2020			2019			% Change *
As a percentage of revenue:
Platforms		17.5	%		18.0	%		(0.5	)%
Transactions		75.8	%		76.4	%		(0.6	)%
Total		68.4	%		70.5	%		(2.1	)%

* The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 2.1%, from 70.5% for the previous year to 68.4%, for the three months ended March 31, 2020.

Category	Impact as percentage of revenue		Key Drivers
Platforms	↓	0.5 %	Decreased primarily due to proportionally lower third-party data costs.
Transactions	↓	0.6 %	Decreased primarily due to proportionally lower copyright and personnel costs.

Cost of Revenue

	Nine Months Ended March 31,
	2020		2019		$ Change		% Change
Cost of Revenue:
Platforms	$	490,897	$	365,007	$	125,890		34.5	%
Transactions		15,552,771		14,838,457		714,254		4.8	%
Total cost of revenue	$	16,043,608	$	15,203,464	$	840,144		5.5	%

	Nine Months Ended March 31,
	2020			2019			% Change *
As a percentage of revenue:
Platforms		17.4	%		18.2	%		(0.8	)%
Transactions		76.4	%		76.8	%		(0.4	)%
Total		69.2	%		71.3	%		(2.1	)%

* The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 2.1%, from 71.3% for the previous year to 69.2%, for the nine months ended March 31, 2020.

Category	Impact as percentage of revenue		Key Drivers
Platforms	↓	0.8 %	Decreased primarily due to proportionally lower third-party data costs.
Transactions	↓	0.4 %	Decreased primarily due to proportionally lower copyright and personnel costs.

Gross Profit

	Three Months Ended March 31,
	2020		2019		$ Change		% Change
Gross Profit:
Platforms	$	839,870	$	614,054	$	225,816		36.8	%
Transactions		1,699,144		1,565,607		133,537		8.5	%
Total gross profit	$	2,539,014	$	2,179,661	$	359,353		16.5	%

	Three Months Ended March 31,
	2020			2019			% Change *
As a percentage of revenue:
Platforms		82.5	%		82.0	%		0.5	%
Transactions		24.2	%		23.6	%		0.6	%
Total		31.6	%		29.5	%		2.1	%

* The difference between current and prior period gross profit as a percentage of revenue

Gross Profit

	Nine Months Ended March 31,
	2020		2019		$ Change		% Change
Gross Profit:
Platforms	$	2,333,162	$	1,640,277	$	692,885		42.2	%
Transactions		4,796,187		4,475,579		320,608		7.2	%
Total gross profit	$	7,129,349	$	6,115,856	$	1,013,493		16.6	%

	Nine Months Ended March 31,
	2020			2019			% Change *
As a percentage of revenue:
Platforms		82.6	%		81.8	%		0.8	%
Transactions		23.6	%		23.2	%		0.4	%
Total		30.8	%		28.7	%		2.1	%

* The difference between current and prior period gross profit as a percentage of revenue

Operating Expenses

	Three Months Ended March 31,
	2020		2019		$ Change			% Change
Operating Expenses:
Sales and marketing	$	626,956	$	542,641	$	84,315			15.5	%
Technology and product development		536,238		537,685		(1,447	)		(0.3	)%
General and administrative		1,230,580		1,129,461		101,119			9.0	%
Depreciation and amortization		5,510		9,617		(4,107	)		(42.7	)%
Stock-based compensation expense		142,237		131,072		11,165			8.5	%
Foreign currency transaction loss (gain)		8,648		2,302		6,346			275.7	%
Total operating expenses	$	2,550,169	$	2,352,778	$	197,391			8.4	%

Category	Impact			Key Drivers
Sales and marketing	↑	$	84,315	Increased primarily due to greater personnel costs.
General and administrative	↑	$	101,119	Increased primarily due to greater personnel costs and NASDAQ entry fee.

	Nine Months Ended March 31,
	2020		2019		$ Change			% Change
Operating Expenses:
Sales and marketing	$	1,816,142	$	1,419,937	$	396,205			27.9	%
Technology and product development		1,584,148		1,590,752		(6,604	)		(0.4	)%
General and administrative		3,732,300		3,428,672		303,628			8.9	%
Depreciation and amortization		19,908		30,465		(10,557	)		(34.7	)%
Stock-based compensation expense		808,541		700,269		108,272			15.5	%
Foreign currency transaction loss (gain)		15,315		17,307		(1,992	)		(11.5	)%
Total operating expenses	$	7,976,354	$	7,187,402	$	788,952			11.0	%

Category	Impact			Key Drivers
Sales and marketing	↑	$	396,205	Increased primarily due to greater personnel costs and advertising media spend.
General and administrative	↑	$	303,628	Increased primarily due to greater personnel costs, professional service fees and NASDAQ entry fee.

Net Income (Loss)

	Three Months Ended March 31,
	2020		2019			$ Change			% Change
Net Income (Loss):
Income (loss) from continuing operations	$	11,946	$	(150,724	)	$	162,670			107.9	%
Income from discontinued operations		-		33,044			(33,044	)		(100.0	)%
Total net income (loss)	$	11,946	$	(117,680	)	$	129,626			110.2	%

Income from continuing operations increased $162,670 or 107.9%, for the three months ended March 31, 2020 compared to the prior year, primarily due to increased gross profit, partially offset by increased operating expenses as described above.

	Nine Months Ended March 31,
	2020			2019			$ Change			% Change
Net Income (Loss):
Loss from continuing operations	$	(779,128	)	$	(1,018,567	)	$	239,439			23.5	%
Income from discontinued operations		117,445			130,462			(13,017	)		(10.0	)%
Total net loss	$	(661,683	)	$	(888,105	)	$	226,422			25.5	%

Loss from continuing operations decreased $239,439 or 23.5%, for the nine months ended March 31, 2020 compared to the prior year, primarily due to increased gross profit, partially offset by increased gross operating expenses as described above.

Liquidity and Capital Resources

	Nine Months Ended March 31,
Consolidated Statements of Cash Flow Data:	2020			2019
Net cash provided by operating activities	$	1,304,131		$	575,130
Net cash used in investing activities		-			(9,107	)
Net cash provided by (used in) financing activities		1,606,463			(159,198	)

Effect of exchange rate changes		(14,424	)		(11,921	)
Net increase in cash and cash equivalents		2,896,170			394,904
Cash and cash equivalents, beginning of period		5,353,090			4,908,180
Cash and cash equivalents, end of period	$	8,249,260		$	5,303,084

Liquidity

As of March 31, 2020, we had cash and cash equivalents of $8,249,260, compared to $5,353,090 as of June 30, 2019, an increase of $2,896,170. This increase was primarily due to cash provided by investing and operating activities.

Operating Activities

Net cash provided by operating activities was $1,304,131 for the nine months ended March 31, 2020 and resulted primarily from an increase in accounts payable and accrued expenses of $1,311,842 and an increase in deferred revenue of $991,981, partially offset by an increase in accounts receivable of $618,324 and an increase in prepaid royalties of $566,379.

Net cash provided by operating activities was $575,130 for the nine months ended March 31, 2019 and resulted primarily from an increase in accounts payable and accrued expenses of $1,047,266 and an increase in deferred revenue of $403,709, partially offset by a net loss of $888,105 and an increase in prepaid royalties of $647,387.

Investing Activities

No cash was used in or provided by investing activities for the nine months ended March 31, 2020.

Net cash used in investing activities was $9,107 for the nine months ended March 31, 2019 and resulted from the purchase of property and equipment.

Financing Activities

Net cash provided by financing activities was $1,606,463 for the nine months ended March 31, 2020 and resulted from the proceeds from the exercise of warrants of $1,875,000, partially offset by the repurchase of common stock of $268,537.

Net cash used in financing activities was $159,198 for the nine months ended March 31, 2019 and resulted from the repurchase of common stock.

We entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 14, 2022, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2020. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest equal to the greater of 1% above the prime rate and 5.5%. The interest rate on the line of credit was 5.5% as of March 31, 2020. The line of credit was secured by our consolidated assets.

There were no outstanding borrowings under the line as of March 31, 2020 and June 30, 2019, respectively. As of March 31, 2020, there was approximately $2,458,000 of available credit.

Non-GAAP Measure – Adjusted EBITDA

In addition to our GAAP results, we present Adjusted EBITDA as a supplemental measure of our performance. However, Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of liquidity. We define Adjusted EBITDA as net income (loss), plus interest expense, other income (expense), foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, income from discontinued operations and gain on sale of discontinued operations. Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three and nine months ended March 31, 2020 and 2019:

	Three Months Ended March 31,
	2020			2019			$ Change
Net income (loss)	$	11,946		$	(117,680	)	$	129,626
Add (deduct):
Other (income) expense		(23,662	)		(27,875	)		4,213
Foreign currency transaction loss (gain)		8,648			2,302			6,346
Provision for income taxes		561			5,482			(4,921	)
Depreciation and amortization		5,510			9,617			(4,107	)
Stock-based compensation		142,237			131,072			11,165
Gain on sale of discontinued operations		-			(33,044	)		33,044
Adjusted EBITDA	$	145,240		$	(30,126	)	$	175,366

	Nine Months Ended March 31,
	2020			2019			$ Change
Net loss	$	(661,683	)	$	(888,105	)	$	226,422
Add (deduct):
Other (income) expense		(75,738	)		(75,124	)		(614	)
Foreign currency transaction loss (gain)		15,315			17,307			(1,992	)
Provision for income taxes		7,861			22,145			(14,284	)
Depreciation and amortization		19,908			30,465			(10,557	)
Stock-based compensation		808,541			700,269			108,272
Gain on sale of discontinued operations		(117,445	)		(130,462	)		13,017
Adjusted EBITDA	$	(3,241	)	$	(323,505	)	$	320,264

We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; and in making compensation decisions and in communications with our board of directors concerning our financial performance. Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following:

Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and

although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2020, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.

Inherent Limitations on the Effectiveness of Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control Over Financial Reporting

In addition, our management with the participation of our principal executive officer and principal financial officer have determined that no change in our internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Exchange Act) occurred during the quarter ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1A. Risk Factors.

The COVID-19 pandemic may reduce the number of articles ordered by our transactional customers, or may reduce the number of platform subscriptions, either of which could have a material adverse impact on our business and financial performance.

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows. However, the COVID-19 pandemic’s continued impact on the economy and our customers may reduce the number of articles ordered by our transactional customers, or may reduce the number of platform subscriptions, either of which could have a material adverse impact on our business and financial performance.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of our financial statements for the fiscal quarter ended March 31, 2020, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2020, we repurchased 25,150 shares of our common stock from employees at an average market price of approximately $2.75 per share for an aggregate amount of $69,163.

As of March 31, 2020, $330,838 remains available under the 2020 plan to repurchase common stock from our employees. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

The following table summarizes repurchases of our common stock on a monthly basis:

Period	Total Number of Shares Purchased ¹	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 2020	-	-	-	$400,000
February 2020	-	-	-	$400,000
March 2020	25,150	$2.75	-	$330,838
Total	25,150	$2.75	-	-

¹ Consists of shares of common stock purchased from an employee to satisfy tax obligations in connection with the vesting of stock incentive awards.

Item 6. Exhibits

See “Exhibit Index” on the page immediately following the signature page hereto for a list of exhibits filed as part of this report, which is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	RESEARCH SOLUTIONS, INC.

	By:	/s/ Peter Victor Derycz

		Peter Victor Derycz
Date: May 14, 2020		Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Alan Louis Urban

		Alan Louis Urban
Date: May 14, 2020		Chief Financial Officer (Principal Financial and Accounting Officer)

EXHIBIT INDEX

Exhibit Number		Description
10.1		Second Amendment to Amended and Restated Loan and Security Agreement dated February 14, 2020, among Silicon Valley Bank, Research Solutions, Inc. and Reprints Desk, Inc.
31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1		Section 1350 Certification of Chief Executive Officer *
32.2		Section 1350 Certification of Chief Financial Officer *
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Furnished herewith

Indicates management contract or compensatory plan